BioCardia (BCDA) AI Stock Analysis

• Market Cap: $8.24M
• Dividend Yield: N/A
• Average Volume (3M): 72.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -87.84%
• EPS Growth: 59.34%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -3.34
• Shares Outstanding: 4,680,005
• 10 Day Avg. Volume: 21,237
• 30 Day Avg. Volume: 72,407
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 171.75
• Price to Cash Flow (P/CF): -1.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 229.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

BioCardia faces significant financial challenges and technical weaknesses, reflected in its low stock score. While recent trial successes and regulatory progress offer some positive prospects, financial instability and market uncertainty weigh heavily on the company's outlook.

Positive Factors

Financial Performance

Biocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.

Financial Stability

The company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.

New Product Launch

Morph DNA Introducer now commercially available, providing new revenue stream.

Negative Factors

Clinical Trial Challenges

The DSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.

Clinical Trial Setback

DSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

How the Company Makes Money

BioCardia primarily makes money through the development and commercialization of its proprietary cell therapy systems. The company's revenue model is largely centered around clinical trials and collaborations with medical institutions for the advancement of its CardiAMP and CardiALLO systems. Revenue streams may include licensing agreements, sales of therapy systems, and milestone payments from partnerships with healthcare organizations and research institutions. BioCardia's earnings are significantly influenced by the successful progression of clinical trials, regulatory approvals, and the subsequent commercialization of its therapeutic products.

BioCardia Financial Statement Overview

Summary

BioCardia's financial performance is weak, with negative EBIT, net income margins, and volatile revenue. The balance sheet shows high leverage risks and stagnant asset growth, while cash flow relies heavily on financing. Overall, the company faces financial instability and challenges in achieving profitability.

Income Statement

BioCardia's income statement indicates significant challenges with profitability, as evidenced by consistently negative EBIT and net income margins. Revenue has been highly volatile, with a dramatic decrease over the years and a substantial dip in gross profit. This volatility, coupled with negative margins, suggests financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet reveals a weak equity position with negative stockholders' equity in previous years, which has slightly improved to a positive figure recently. The debt-to-equity ratio is relatively high, indicating potential leverage risks. Despite an increase in cash and short-term investments, overall asset growth has been stagnant, raising concerns about long-term financial health.

Cash Flow

The cash flow statement shows consistently negative free cash flow, although there has been some improvement in operating cash flow relative to net income. High reliance on financing activities to manage cash flow needs highlights challenges in generating sufficient operating cash. This reliance on external financing can be risky if not managed carefully.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
58.00K	477.00K	1.35M	1.01M	145.00K
	Gross Profit
58.00K	-7.25M	-10.55M	375.00K	141.00K
	EBIT
-8.00M	-11.64M	-11.90M	-12.63M	-15.53M
	EBITDA
-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
	Net Income Common Stockholders
-7.95M	-11.57M	-11.91M	-12.62M	-15.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.37M	1.10M	7.36M	12.87M	21.41M
	Total Assets
3.72M	2.99M	9.79M	15.72M	23.42M
	Total Debt
951.00K	1.31M	1.63M	1.87M	614.00K
	Net Debt
-1.42M	212.00K	-5.73M	-11.00M	-20.79M
	Total Liabilities
2.89M	4.59M	4.90M	5.34M	4.25M
	Stockholders Equity
837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow		Free Cash Flow
-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
	Operating Cash Flow
-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
	Investing Cash Flow
-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
	Financing Cash Flow
9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Negative. The current price of 1.82 is below the 20-day moving average (MA) of 2.07, below the 50-day MA of 2.33, and below the 200-day MA of 2.49, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 36.94 is Neutral, neither overbought nor oversold. The STOCH value of 25.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
BRTX	51 Neutral	$12.68M	―	-96.89%	―	175.03%	55.34%
CTXR	38 Underperform	$7.68M	―	-52.85%	―	―	8.99%
SNSE	38 Underperform	$8.73M	―	-58.40%	―	―	1.00%
HCWB	36 Underperform	$8.94M	―	-897.37%	―	-9.68%	-13.26%
BCDA	34 Underperform	$8.24M	―	-737.89%	―	-87.84%	59.34%
LPTX	34 Underperform	$15.93M	―	-141.94%	―	―	64.01%

BioCardia Corporate Events

BioCardia’s CardiALLO Trial Advances After Safety Review

On April 15, 2025, BioCardia announced that the independent Data Safety Monitoring Board recommended the continuation of the CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial, following a positive review of the 30-day safety data. The trial, which showed no major adverse cardiac events or immune reactions, is set to progress with the enrollment of 39 participants in the United States. This development is significant for BioCardia’s MSC platform, potentially aiding discussions around funding and partnerships, and could lead to future pivotal trials and approvals in the USA and Japan.

Spark’s Take on BCDA Stock

According to Spark, TipRanks’ AI Analyst, BCDA is a Underperform.

BioCardia faces significant financial challenges, with ongoing losses and high volatility in revenue growth. While technical indicators suggest a potential rebound, the company’s valuation remains unattractive due to negative earnings. Positive trial results and financial improvements from the earnings call provide some optimism, but the failure to meet primary endpoints and unexpected market reactions highlight ongoing risks.

To see Spark’s full report on BCDA stock, click here.

BioCardia Clarifies Timing for CardiAMP-HF Results Call

On March 31, 2025, BioCardia, Inc. announced a clarification regarding the timing of its conference call to discuss the two-year CardiAMP-HF results. Initially reported to occur at 4:30pm PDT, the call was confirmed to take place at 4:30pm EDT. This announcement ensures stakeholders are informed of the correct timing to access the call, which is crucial for maintaining transparency and effective communication regarding the company’s clinical progress.

BioCardia Reports Positive Phase 3 CardiAMP-HF Results

On March 31, 2025, BioCardia announced the two-year outcomes of its Phase 3 CardiAMP-HF study, revealing that its autologous cell therapy significantly improved survival, reduced major adverse cardiac and cerebrovascular events, and enhanced quality of life in ischemic heart failure patients with reduced ejection fraction. The study, involving 115 patients across 18 centers in the U.S. and Canada, showed particularly strong results in patients with elevated NTproBNP biomarkers, indicating the therapy’s potential to address a significant unmet need in heart failure treatment and reduce healthcare costs.